JP5165688B2 - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- JP5165688B2 JP5165688B2 JP2009535119A JP2009535119A JP5165688B2 JP 5165688 B2 JP5165688 B2 JP 5165688B2 JP 2009535119 A JP2009535119 A JP 2009535119A JP 2009535119 A JP2009535119 A JP 2009535119A JP 5165688 B2 JP5165688 B2 JP 5165688B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- propylsulfanyl
- acetic acid
- piperidyl
- cyclohexylcarbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *NC(c(ccc(**C(O)=O)n1)c1S*)=O Chemical compound *NC(c(ccc(**C(O)=O)n1)c1S*)=O 0.000 description 3
- MCLMRYSQPCRLTD-UHFFFAOYSA-N CCCCc1nc(Cl)ccc1C(NC1C2CC(C3)CC1CC3C2)=O Chemical compound CCCCc1nc(Cl)ccc1C(NC1C2CC(C3)CC1CC3C2)=O MCLMRYSQPCRLTD-UHFFFAOYSA-N 0.000 description 1
- CULOQDXMEBSGMA-OAHLLOKOSA-N CCCSc(nc(c(F)c1)N2C[C@@H](CC(O)=O)CCC2)c1C(NC1CCCCC1)=O Chemical compound CCCSc(nc(c(F)c1)N2C[C@@H](CC(O)=O)CCC2)c1C(NC1CCCCC1)=O CULOQDXMEBSGMA-OAHLLOKOSA-N 0.000 description 1
- MTFZRWFFBLVPPD-UHFFFAOYSA-N CCCSc(nc(cc1)Cl)c1C(N(C)C1CCOCC1)=O Chemical compound CCCSc(nc(cc1)Cl)c1C(N(C)C1CCOCC1)=O MTFZRWFFBLVPPD-UHFFFAOYSA-N 0.000 description 1
- JUTHJRBYVYXCEL-UHFFFAOYSA-N CN(CCc1ccccc1)c(nc(cc1)Cl)c1C(NC1CCCCC1)=O Chemical compound CN(CCc1ccccc1)c(nc(cc1)Cl)c1C(NC1CCCCC1)=O JUTHJRBYVYXCEL-UHFFFAOYSA-N 0.000 description 1
- OAXNAMZFFFUADC-UHFFFAOYSA-N Cc1nc(Cl)ccc1C(NC1CCCCC1)=O Chemical compound Cc1nc(Cl)ccc1C(NC1CCCCC1)=O OAXNAMZFFFUADC-UHFFFAOYSA-N 0.000 description 1
- UYFINTSPYHNTIK-UHFFFAOYSA-N O=C(c(cc1)cnc1Cl)NC1CCCCC1 Chemical compound O=C(c(cc1)cnc1Cl)NC1CCCCC1 UYFINTSPYHNTIK-UHFFFAOYSA-N 0.000 description 1
- MWYRXSBQSPYSFZ-UHFFFAOYSA-N O=C(c(ccc(Cl)n1)c1SCCc1ccccc1)NC1CCCCC1 Chemical compound O=C(c(ccc(Cl)n1)c1SCCc1ccccc1)NC1CCCCC1 MWYRXSBQSPYSFZ-UHFFFAOYSA-N 0.000 description 1
- VITSFVDSKDDGBL-MSGKNJCLSA-N OC(C[C@H](CCC1)CN1c1ccc(C(NC(C(CC2)C3)C(C4)C2CC[C@@]34OC(F)F)=O)c(SC2CCCC2)n1)=O Chemical compound OC(C[C@H](CCC1)CN1c1ccc(C(NC(C(CC2)C3)C(C4)C2CC[C@@]34OC(F)F)=O)c(SC2CCCC2)n1)=O VITSFVDSKDDGBL-MSGKNJCLSA-N 0.000 description 1
- IEXLKXKWZOFZGK-GTMBWIDFSA-N OC([C@@H]1[C@@H](C2)[C@H]1CN2c1ccc(C(N(CC2)CC2c2cnccc2)=O)c(SC2CCCC2)n1)=O Chemical compound OC([C@@H]1[C@@H](C2)[C@H]1CN2c1ccc(C(N(CC2)CC2c2cnccc2)=O)c(SC2CCCC2)n1)=O IEXLKXKWZOFZGK-GTMBWIDFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86424706P | 2006-11-03 | 2006-11-03 | |
| US86430306P | 2006-11-03 | 2006-11-03 | |
| US60/864,303 | 2006-11-03 | ||
| US60/864,247 | 2006-11-03 | ||
| PCT/GB2007/004131 WO2008053194A2 (en) | 2006-11-03 | 2007-10-31 | Pyridine carboxamides as 11-beta-hsd1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010508338A JP2010508338A (ja) | 2010-03-18 |
| JP2010508338A5 JP2010508338A5 (enExample) | 2012-08-16 |
| JP5165688B2 true JP5165688B2 (ja) | 2013-03-21 |
Family
ID=39304797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535119A Active JP5165688B2 (ja) | 2006-11-03 | 2007-10-31 | 化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US7964618B2 (enExample) |
| EP (2) | EP2233480B1 (enExample) |
| JP (1) | JP5165688B2 (enExample) |
| KR (1) | KR101465275B1 (enExample) |
| CN (3) | CN102603711A (enExample) |
| AR (1) | AR063458A1 (enExample) |
| AT (1) | ATE475649T1 (enExample) |
| AU (1) | AU2007315955B2 (enExample) |
| BR (1) | BRPI0717970C1 (enExample) |
| CA (1) | CA2668006C (enExample) |
| CL (1) | CL2007003176A1 (enExample) |
| CO (1) | CO6321130A2 (enExample) |
| CY (1) | CY1110813T1 (enExample) |
| DE (1) | DE602007008137D1 (enExample) |
| DK (1) | DK2086939T3 (enExample) |
| ES (2) | ES2347491T3 (enExample) |
| HR (1) | HRP20100522T1 (enExample) |
| IL (1) | IL198231A0 (enExample) |
| MX (1) | MX2009004707A (enExample) |
| NO (1) | NO20091603L (enExample) |
| NZ (1) | NZ576501A (enExample) |
| PE (1) | PE20081487A1 (enExample) |
| PL (1) | PL2086939T3 (enExample) |
| PT (1) | PT2086939E (enExample) |
| RS (1) | RS51451B (enExample) |
| RU (1) | RU2451674C2 (enExample) |
| SI (1) | SI2086939T1 (enExample) |
| TW (1) | TW200827346A (enExample) |
| UY (1) | UY30681A1 (enExample) |
| WO (1) | WO2008053194A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324265B2 (en) | 2005-11-21 | 2012-12-04 | Shionogi & Co., Ltd. | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity |
| TW200827346A (en) * | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| TW200836719A (en) * | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| ES2535317T3 (es) | 2007-05-18 | 2015-05-08 | Shionogi & Co., Ltd. | Derivado heterocíclico que contiene nitrógeno que tiene actividad inhibidora de la 11 beta-hidroxiesteroide deshidrogenasa de tipo 1 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009051112A1 (ja) * | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | アミド化合物およびその用途 |
| WO2009056881A1 (en) * | 2007-10-29 | 2009-05-07 | Astrazeneca Ab | Chemical compounds 313 |
| AU2009211215B2 (en) * | 2008-02-04 | 2011-11-03 | Astrazeneca Ab | Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid |
| UY31774A (es) * | 2008-04-22 | 2009-12-14 | Astrazeneca Ab | Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos |
| EP2243479A3 (en) | 2009-04-20 | 2011-01-19 | Abbott Laboratories | Novel amide and amidine derivates and uses thereof |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| TW201118085A (en) * | 2009-10-20 | 2011-06-01 | Astrazeneca Ab | Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 11-β-HSD1 |
| MX2012006028A (es) * | 2009-11-24 | 2012-06-19 | Allergan Inc | Compuestos novedosos como moduladores de receptor con utilidad terapeutica. |
| WO2011068927A2 (en) * | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| PE20131394A1 (es) | 2010-09-23 | 2014-01-11 | Abbvie Inc | Monohidrato de derivados de aza-adamantano |
| US8471027B2 (en) * | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
| JP5697800B2 (ja) * | 2011-07-21 | 2015-04-08 | シュエンジュウ・ファーマ・カンパニー・リミテッド | 複素環置換ピリミジン化合物 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN102659657B (zh) * | 2012-04-24 | 2014-08-06 | 徐州医学院 | 一种蛋白酶抑制剂pf429242的合成方法 |
| SG11201407229UA (en) | 2012-06-20 | 2014-12-30 | Hoffmann La Roche | Substituted pyrazole compounds as lpar antagonists |
| JP2015520202A (ja) | 2012-06-20 | 2015-07-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｌｐａｒ拮抗薬としてのｎ−アルキルトリアゾール化合物 |
| EP3821892A1 (en) * | 2019-11-12 | 2021-05-19 | University of Leeds | (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds |
| GB202216324D0 (en) * | 2022-11-02 | 2022-12-14 | Cerevance Ltd | Novel compounds |
| GB202408335D0 (en) | 2024-06-11 | 2024-07-24 | Astrazeneca Ab | Therapies for wound treatment |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR66581B (enExample) | 1978-02-21 | 1981-03-27 | Delalande Sa | |
| US4734418A (en) | 1984-12-14 | 1988-03-29 | Mitsui Petrochemical Industries, Ltd. | Quinazoline compounds and antihypertensives |
| CN1374953A (zh) | 1999-09-16 | 2002-10-16 | 田边制药株式会社 | 含氮的6－员芳香环化合物 |
| FR2803592A1 (fr) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant. |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| WO2002020463A2 (en) | 2000-09-05 | 2002-03-14 | Tularik Inc. | Fxr modulators |
| CA2426430C (en) | 2000-10-20 | 2014-10-07 | Biocryst Pharmaceuticals, Inc. | Biaryl compounds as serine protease inhibitors |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| JP2005528395A (ja) | 2002-04-05 | 2005-09-22 | ザ ユニバーシティ オブ エディンバラ | 組成物 |
| WO2004039795A2 (en) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| SE0300458D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| US7432287B2 (en) | 2003-02-26 | 2008-10-07 | Banyu Pharmeceutical Co., Ltd. | Heteroarylcarbamoylbenzene derivative |
| ATE482747T1 (de) | 2003-04-11 | 2010-10-15 | High Point Pharmaceuticals Llc | Neue amide derivate und deren pharmazeutische verwendungen |
| EP1653949A4 (en) | 2003-08-07 | 2009-04-22 | Merck & Co Inc | PYRAZOL CARBOXAMIDE AS AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 |
| WO2005023761A2 (en) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| EP1696915A1 (en) | 2003-12-19 | 2006-09-06 | Pfizer, Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| DE602005009500D1 (de) | 2004-02-24 | 2008-10-16 | Glaxo Group Ltd | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors |
| US7423147B2 (en) * | 2004-03-31 | 2008-09-09 | Janssen Pharmaceutical, N.V. | Pyridine compounds as histamine H3 modulators |
| JP2007536369A (ja) | 2004-05-06 | 2007-12-13 | ファイザー・インク | プロリン及びモルホリン誘導体の新規化合物 |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| CA2571361C (en) | 2004-06-28 | 2011-07-26 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as 11beta-hsd1 inhibitors |
| US20090093463A1 (en) | 2004-11-02 | 2009-04-09 | Agouron Pharmaceuticals Inc. | Novel compounds of substituted and unsubtituted adamantyl amides |
| US7767680B2 (en) | 2004-11-03 | 2010-08-03 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| MX2007008238A (es) | 2005-01-05 | 2007-08-17 | Abbott Lab | Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1. |
| EP1928840B1 (en) | 2005-04-05 | 2011-08-10 | F. Hoffmann-La Roche AG | 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors |
| RU2404164C2 (ru) | 2005-04-06 | 2010-11-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридин-3-карбоксамида в качестве обратных агонистов св1 |
| WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| EP1891069A1 (en) | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
| TW200716576A (en) | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| KR100970294B1 (ko) | 2005-06-08 | 2010-07-15 | 니뽄 다바코 산교 가부시키가이샤 | 복소환 화합물 |
| CA2610903A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | N-(pyridin-2-yl)-sulfonamide derivatives |
| KR101346902B1 (ko) | 2005-07-09 | 2014-01-02 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체 |
| JP2009504621A (ja) | 2005-08-09 | 2009-02-05 | アストラゼネカ アクチボラグ | 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体 |
| CA2627813A1 (en) | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted pyrrolones as allosteric modulators of glucokinase |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| US8324265B2 (en) | 2005-11-21 | 2012-12-04 | Shionogi & Co., Ltd. | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity |
| AU2007210018A1 (en) | 2006-01-31 | 2007-08-09 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| HUE026011T2 (en) | 2006-03-22 | 2016-05-30 | Hoffmann La Roche | Pyrazoles as 11-beta-HSD-1 |
| KR20090014347A (ko) | 2006-04-07 | 2009-02-10 | 하이 포인트 파마슈티칼스, 엘엘씨 | 11β-히드록시스테로이드 탈수소효소 타입 1 활성 화합물 |
| CN101431994A (zh) | 2006-04-27 | 2009-05-13 | 索尔瓦药物有限公司 | CBx大麻素受体调节剂作为钾通道调节剂的用途 |
| US20100022589A1 (en) | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| ES2535317T3 (es) | 2007-05-18 | 2015-05-08 | Shionogi & Co., Ltd. | Derivado heterocíclico que contiene nitrógeno que tiene actividad inhibidora de la 11 beta-hidroxiesteroide deshidrogenasa de tipo 1 |
| ES2423181T3 (es) | 2007-07-17 | 2013-09-18 | F. Hoffmann-La Roche Ag | Inhibidores de la 11ß-hidroxiesteroide-deshidrogenasa |
| CN101909621A (zh) | 2007-11-06 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | 4-[4-(2-金刚烷基氨基甲酰基)-5-叔丁基-吡唑-1-基]苯甲酸-465 |
| AU2009211215B2 (en) | 2008-02-04 | 2011-11-03 | Astrazeneca Ab | Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid |
| UY31774A (es) | 2008-04-22 | 2009-12-14 | Astrazeneca Ab | Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos |
| CN102300851A (zh) | 2009-01-30 | 2011-12-28 | 阿斯利康(瑞典)有限公司 | 制备含羧基的吡唑酰氨基化合物597的新方法 |
| TW201118085A (en) | 2009-10-20 | 2011-06-01 | Astrazeneca Ab | Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 11-β-HSD1 |
-
2007
- 2007-10-29 TW TW096140633A patent/TW200827346A/zh unknown
- 2007-10-30 US US11/928,744 patent/US7964618B2/en active Active
- 2007-10-31 EP EP10163730.4A patent/EP2233480B1/en active Active
- 2007-10-31 RU RU2009115830/04A patent/RU2451674C2/ru active
- 2007-10-31 DE DE602007008137T patent/DE602007008137D1/de active Active
- 2007-10-31 PL PL07824375T patent/PL2086939T3/pl unknown
- 2007-10-31 HR HR20100522T patent/HRP20100522T1/hr unknown
- 2007-10-31 MX MX2009004707A patent/MX2009004707A/es active IP Right Grant
- 2007-10-31 RS RSP-2010/0422A patent/RS51451B/sr unknown
- 2007-10-31 EP EP07824375A patent/EP2086939B8/en active Active
- 2007-10-31 CN CN2012100119350A patent/CN102603711A/zh active Pending
- 2007-10-31 CA CA2668006A patent/CA2668006C/en active Active
- 2007-10-31 DK DK07824375.5T patent/DK2086939T3/da active
- 2007-10-31 UY UY30681A patent/UY30681A1/es not_active Application Discontinuation
- 2007-10-31 AU AU2007315955A patent/AU2007315955B2/en active Active
- 2007-10-31 CN CN2007800491675A patent/CN101573336B/zh not_active Expired - Fee Related
- 2007-10-31 ES ES07824375T patent/ES2347491T3/es active Active
- 2007-10-31 CN CN2010101438299A patent/CN101787016B/zh active Active
- 2007-10-31 JP JP2009535119A patent/JP5165688B2/ja active Active
- 2007-10-31 BR BRPI0717970A patent/BRPI0717970C1/pt active IP Right Grant
- 2007-10-31 KR KR1020097010339A patent/KR101465275B1/ko active Active
- 2007-10-31 SI SI200730335T patent/SI2086939T1/sl unknown
- 2007-10-31 ES ES10163730T patent/ES2423206T3/es active Active
- 2007-10-31 NZ NZ576501A patent/NZ576501A/en not_active IP Right Cessation
- 2007-10-31 PT PT07824375T patent/PT2086939E/pt unknown
- 2007-10-31 WO PCT/GB2007/004131 patent/WO2008053194A2/en not_active Ceased
- 2007-10-31 AT AT07824375T patent/ATE475649T1/de active
- 2007-11-02 CL CL200703176A patent/CL2007003176A1/es unknown
- 2007-11-02 AR ARP070104887A patent/AR063458A1/es not_active Application Discontinuation
- 2007-11-05 PE PE2007001517A patent/PE20081487A1/es not_active Application Discontinuation
-
2009
- 2009-04-20 IL IL198231A patent/IL198231A0/en unknown
- 2009-04-22 NO NO20091603A patent/NO20091603L/no not_active Application Discontinuation
- 2009-04-29 CO CO09043382A patent/CO6321130A2/es not_active Application Discontinuation
- 2009-08-14 US US12/541,565 patent/US8673938B2/en not_active Expired - Fee Related
- 2009-08-14 US US12/541,574 patent/US20090312372A1/en not_active Abandoned
-
2010
- 2010-10-04 CY CY20101100879T patent/CY1110813T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5165688B2 (ja) | 化合物 | |
| CN103429585B (zh) | 作为白细胞介素-1受体相关激酶抑制剂的吲唑基三唑衍生物 | |
| US20090264401A1 (en) | Substituted pyrimidin-5-carboxamides 281 | |
| BRPI0708264A2 (pt) | piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina | |
| CZ3799A3 (cs) | Indolový derivát k ošetřování osteoporézy | |
| HK1135090B (en) | Pyridine carboxamides as 11-beta-hsd1 inhibitors | |
| SA07280596B1 (ar) | مركبات بيريدين الأميد وأستخدامها كمثبطات إنزيم β-11 هيدروكسى ستيرويد ديهيدروجينيز من النوع الأول | |
| HK1191938B (en) | Indazolyl triazole derivatives as irak inhibitors | |
| MXPA06008934A (en) | Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101027 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101027 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120628 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20120628 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20120718 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120723 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121023 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121026 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121030 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121119 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121219 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151228 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5165688 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |